JW Shinyak Corporation Cash Flow Conversion Efficiency
JW Shinyak Corporation cash flow conversion efficiency. Based on the latest financial reports, JW Shinyak Corporation (067290) has a cash flow conversion efficiency ratio of 0.115x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.46 Billion ≈ $3.03 Million USD) by net assets (₩38.73 Billion ≈ $26.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of JW Shinyak Corporation (2007–2024)
Cash flow conversion efficiency of JW Shinyak Corporation from 2007 to 2024. This chart illustrates how JW Shinyak Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 067290 live share price for real-time trading data and today's change.
JW Shinyak Corporation Cash Flow Conversion Ratio Explained
JW Shinyak Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
JW Shinyak Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of JW Shinyak Corporation ranked by their cash flow conversion efficiency. Also see JW Shinyak Corporation stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
A SPAC II Acquisition Corp. Ordinary Shares
NASDAQ:ASCB
|
0.036x |
|
Cube Entertainment Inc
KQ:182360
|
-0.108x |
|
Computacenter PLC
LSE:CCC
|
-0.097x |
|
Rani Therapeutics Holdings Inc
NASDAQ:RANI
|
-0.188x |
|
Protech Mitra Perkasa Tbk PT
JK:OASA
|
-0.061x |
|
Daewon Media Co. Ltd
KQ:048910
|
0.095x |
|
G J Steel Public Company Limited
BK:GJS
|
0.051x |
|
Space Shuttle Hi-Tech Co Ltd
TW:2440
|
-0.127x |
Annual Cash Flow Conversion Efficiency for JW Shinyak Corporation (2007–2024)
The table below shows the annual cash flow conversion efficiency of JW Shinyak Corporation from 2007 to 2024. Review JW Shinyak Corporation free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩26.90 Billion ≈ $18.23 Million |
₩8.44 Billion ≈ $5.72 Million |
0.314x | +101.71% |
| 2023-12-31 | ₩16.44 Billion ≈ $11.14 Million |
₩2.56 Billion ≈ $1.73 Million |
0.156x | +22.16% |
| 2022-12-31 | ₩55.97 Billion ≈ $37.93 Million |
₩7.13 Billion ≈ $4.83 Million |
0.127x | -9.16% |
| 2021-12-31 | ₩55.44 Billion ≈ $37.57 Million |
₩7.77 Billion ≈ $5.27 Million |
0.140x | +93.40% |
| 2020-12-31 | ₩56.56 Billion ≈ $38.33 Million |
₩4.10 Billion ≈ $2.78 Million |
0.072x | +11.25% |
| 2019-12-31 | ₩66.14 Billion ≈ $44.82 Million |
₩4.31 Billion ≈ $2.92 Million |
0.065x | -70.53% |
| 2018-12-31 | ₩33.49 Billion ≈ $22.69 Million |
₩7.40 Billion ≈ $5.02 Million |
0.221x | +426.23% |
| 2017-12-31 | ₩36.83 Billion ≈ $24.96 Million |
₩-2.50 Billion ≈ $-1.69 Million |
-0.068x | -451.98% |
| 2016-12-31 | ₩38.60 Billion ≈ $26.16 Million |
₩743.20 Million ≈ $503.66K |
0.019x | +3608.61% |
| 2015-12-31 | ₩40.23 Billion ≈ $27.26 Million |
₩-22.08 Million ≈ $-14.96K |
-0.001x | +98.99% |
| 2014-12-31 | ₩42.46 Billion ≈ $28.77 Million |
₩-2.31 Billion ≈ $-1.56 Million |
-0.054x | -246.92% |
| 2011-12-31 | ₩52.81 Billion ≈ $35.79 Million |
₩1.95 Billion ≈ $1.32 Million |
0.037x | -65.66% |
| 2007-12-31 | ₩27.49 Billion ≈ $18.63 Million |
₩2.96 Billion ≈ $2.01 Million |
0.108x | -- |
About JW Shinyak Corporation
JW Shinyak Corporation, a pharmaceutical company, engages in the production and sale of medicines and medical supplies in South Korea. The company offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesi… Read more